Current Report Filing (8-k)
March 13 2023 - 6:04AM
Edgar (US Regulatory)
false 0001463361 0001463361 2023-03-10 2023-03-10
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 10, 2023
UNITY BIOTECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware |
|
001-38470 |
|
26-4726035 |
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(IRS Employer Identification No.) |
285 East Grand Ave.
South San Francisco, CA 94080
(Address of principal executive offices, including Zip Code)
Registrant’s telephone number, including area code: (650) 416-1192
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.0001 per share |
|
UBX |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
Unity Biotechnology, Inc. (“Unity”) is aware of media reports indicating that Silicon Valley Bank (“SVB”) has been closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation as receiver. Unity considers its exposure to any liquidity concern at SVB to be limited, given that cash held at SVB is approximately $2.8 million as of March 10, 2023. Unity also maintains a deposit account at SVB under a standby letter of credit issued pursuant to its office lease for approximately $0.9 million. Outside institutions serve as custodians for third-party investments held in Unity’s name, which we believe are not directly exposed to any consequences of a liquidity concern at SVB.
The information in this Item 7.01 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01 shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
UNITY BIOTECHNOLOGY, INC. |
|
|
|
|
Date: March 10, 2023 |
|
|
|
By: |
|
/s/ Lynne Sullivan |
|
|
|
|
|
|
Lynne Sullivan |
|
|
|
|
|
|
Chief Financial Officer |
UNITY Biotechnology (NASDAQ:UBX)
Historical Stock Chart
From Jun 2024 to Jul 2024
UNITY Biotechnology (NASDAQ:UBX)
Historical Stock Chart
From Jul 2023 to Jul 2024